Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Regadenoson (Lexiscan) Clear all
Completed Not applicable Interventional Results available

Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)

NCT01482169
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
FFR Measurement with IV Adenoscan® then with Regadenoson
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

NCT01021865
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Sep 3, 2026, 7:41 PM EDT
Completed No phase listed Observational

Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

NCT02697877
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

NCT02130453
View directory record Official record
Conditions
Ischemia
Interventions
Regadenoson
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET

NCT01109992
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Exercise plus Regadenoson (Lexercise), Regadenoson (Lexiscan)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

NCT01710254
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease
Interventions
Regadenoson MRI, Gadobenate dimeglumine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

NCT03249272
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

NCT01778218
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 3, 2026, 7:41 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

NCT03072589
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson infusion
Drug
Lead sponsor
Christine Lau, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

NCT01085201
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Lexiscan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

NCT01919450
View directory record Official record
Conditions
Myocardial Blood Flow Reserve
Interventions
Regadenoson, Rubidium-82
Drug · Radiation
Lead sponsor
Timothy M. Bateman, MD
Industry
Eligibility
40 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
PET MPI, SPECT MPI, Pharmacological stress agents
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311
View directory record Official record
Conditions
Microvascular Coronary Artery Disease
Interventions
SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 3, 2026, 7:41 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT04600115
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
Drug · Procedure
Lead sponsor
Versiti Blood Health
Other
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Not applicable Interventional Results available

Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

NCT01021618
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia
Interventions
Regadenoson, Symptom-limited exercise
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
30 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress Testing and Cardiac Magnetic Resonance

NCT00871260
View directory record Official record
Conditions
Coronary Disease
Interventions
regadenoson
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

NCT01918995
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

NCT02589977
View directory record Official record
Conditions
Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
Interventions
regadenoson
Drug
Lead sponsor
Marvin W. Kronenberg, M.D.
Other
Eligibility
50 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 3, 2026, 7:41 PM EDT